Pro Feature
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
Accord Biopharma
NC - Raleigh
TOPOTECAN HYDROCHLORIDE (topotecan) by Accord Biopharma is topoisomerase inhibitors [moa]. Approved for lung cancer. First approved in 2017.
Drug data last refreshed 20h ago
Topoisomerase Inhibitors
Topoisomerase Inhibitor
Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms
Organoid-guided vs Topotecan Therapy in Relapsed Extensive-Stage Small Cell Lung Cancer
Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC
A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03)
Trilaciclib vs Placebo in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Topotecan
Worked on TOPOTECAN HYDROCHLORIDE at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo